Key result
Personalized medicine utilizing biomarkers, advanced imaging, and sequencing can help establish individualized treatments to prevent transition from acute myocarditis to persistent heart failure.
A personalized approach using advanced diagnostic tools is essential for understanding and treating inflammatory cardiomyopathy to prevent progression to chronic heart failure.
Does not yet support routine personalized approaches in myocarditis; leaves open validation through prospective trials.
Inflammatory cardiomyopathy is the result of persistent myocardial inflammation which can arise from both infectious or noninfectious causes. While most patients with acute myocarditis recover, up to 20% develop inflammatory cardiomyopathy with chronic heart failure. The interaction between host factors and factors of the agent that triggered myocardial inflammation must be considered to fully understand the individual mechanism of disease. Several inflammatory biomarkers, histology, immunohistochemistry, advanced imaging technologies as well as molecular high-throughput sequencing techniques help to identify disease pathways and to establish a comprehensive, individualized treatment approach, which can include anti-inflammatory medication, antiviral drugs and heart failure therapy. This might help to prevent transition from acute inflammation to persistent heart failure and to restore cardiac function.
No takes yet. Share an insight, caveat, or question.
Neupane et al. (2018) conducted a review in Inflammatory cardiomyopathy. Personalized medicine was evaluated. Personalized medicine utilizing biomarkers, advanced imaging, and sequencing can help establish individualized treatments to prevent transition from acute myocarditis to persistent heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: